Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab
Status:
Withdrawn
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This exploratory study uses [18F] Fluciclatide and Positron emission tomography (PET) imaging
in patients with glioblastoma multiforme (GBM) to be treated with Bevacizumab. The primary
objective of this study is to determine the association of [18F] Fluciclatide uptake,
fludeoxyglucose (FDG) uptake, and tumor blood flow/perfusion determined with H215O and
Magnetic resonance imaging (MRI) and correlate these variables with time to progression (TTP)
in participants with GBM treated with Bevacizumab.